Volume 6, Issue 3 Special Edition, September 2015

Volume 6, Issue 3 Special Edition, September 2015

Index

CONGRESS NEWS

Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma


Longer acting agents for the treatment of bleeding disorders


New genetic variants in GFI1B discovered in patients with bleeding and platelet disorders


Polyphosphate, a modulator of hemostasis and thrombosis: a novel target for antithrombotic agents?


Management of thrombosis in Paroxysmal Nocturnal Hemoglobinuria


New treatment options for patients with inadequately controlled polycythemia vera


JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis


Luspatercept increases hemoglobin and decreases the transfusion need in patients with low-, and intermediate-1 myelodysplastic syndrome


Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma


Adding elotuzumab to standard treatment for multiple myeloma delays disease progression


Multiple myeloma is different in elderly patients


Monitoring deep response in chronic myeloid leukaemia: new methodologies and innovative technologies


Immunotherapy: a new era in the management of lymphoma and multiple myeloma?


Prevention of febrile neutropenia with prophylactic G-CSF improves outcome


Highlights in Non-Hodgkin’s Lymphoma


Advances in Acute Myeloid Leukaemia: Increased insights in chemoresistance and first randomised evidence for kinase inhibition


Venetoclax-rituximab induces deep responses in relapsed CLL


Driver mutations and their evolution in CLL


Blinatumomab: new hope for patients with relapsed/refractory acute lymphoblastic leukemia

T. Feys


Inotuzumab ozogamicin (InO) shows promising efficacy and safety in ALL


When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?


Optimizing patient outcomes in CML


X